Sagimet Biosciences Inc. (SGMT) stock

SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$10.22−0.71 (-6.50%)

Close on Nov 13, 2026Market cap $635.26MP/E –Yield –

Sagimet Biosciences gross margin

Gross margin is gross profit as a percentage of revenue.

Sagimet Biosciences has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?